Metacrine, Inc. Profile Avatar - Palmy Investing

Metacrine, Inc.

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative …

Biotechnology
US, San Diego [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Metacrine, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of MTCR's Analysis
CIK: 1634379 CUSIP: 59101E103 ISIN: US59101E1038 LEI: - UEI: -
Secondary Listings
MTCR has no secondary listings inside our databases.